Targeting LIG1 with PARP Inhibitors: E New Target Identified Using CRISPR
/0 Comments/in CRISPR, PARPi, Preclinical Research/by MaxNew Nanoparticle Therapy Holds Promise for Prostate Cancer Patients
/0 Comments/in Delivery, Preclinical Research/by MaxRepurposing FDA-Approved Drugs for PIM-1 Kinase Inhibition: A Potential Avenue for Prostate Cancer
/0 Comments/in Drug repurposing, Preclinical Research/by MaxNew Hope for Neuroendocrine Prostate Cancer: Targeting Mitochondrial HSP60
/0 Comments/in Preclinical Research/by MaxCRISPR Gene Editing Silences Cancer-Causing Mutations
/0 Comments/in CRISPR, Not PCa related, Preclinical Research/by MaxNew Research Reveals Novel Method to Starve Prostate Cancer Tumors
/0 Comments/in Preclinical Research/by MaxDinuclear Platinum(II) Complexes: A Promising New Chemotherapy to Treating Prostate Cancer
/0 Comments/in Chemotherapy, Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ATM bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus PARP inhibitor personalized medicine prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- Phase 1 Trial of a Triple Combination: 177Lu-PSMA-I&T, Olaparib, and Pembrolizumab July 30, 2025
- LYA914: A Novel Oral PROTAC Targeting Androgen Receptor Variants in Prostate Cancer July 30, 2025
- Phase 1/2 Trial for DS-3939a: A Novel TA-MUC1–Directed ADC for Advanced Prostate Cancer and Beyond July 29, 2025
- AI Platform Aims to Revolutionize Cancer Immunotherapy July 28, 2025